Summary
This study is looking at whether a medicine called surovatamig, given as an injection under the skin, can help people with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) keep the cancer under control after they have completed their standard treatment.
The aim of the study is to find out whether surovatamig can help prevent CLL or SLL from returning or worsening, while also assessing its safety and side effects.
Who can take part?
You may be eligible for this study if:
- you have CLL or SLL
- your cancer has a genetic feature called unmutated IGHV (uIGHV)
- you have completed first-line treatment and your cancer responded to treatment
The study has two parts.
Dose-finding and safety phase
A small number of participants will receive different doses of surovatamig to help determine the most appropriate dose to use in the main study. Researchers will also monitor safety and side effects.
Main Phase III study
Participants who have completed their standard treatment for CLL or SLL will be randomly assigned (by chance) to one of two groups:
- Surovatamig group: receives surovatamig as consolidation treatment to help keep the cancer under control.
- Observation group: receives no additional treatment but is monitored closely.